Haleon Pakistan Limited (PSX:HALEON)

Market Cap	104.51B +6.3%
Revenue (ttm)	41.88B +18.3%
Net Income	5.96B +67.0%
EPS	50.93 +67.0%
Shares Out	117.05M
PE Ratio	17.53
Forward PE	14.79
Dividend	30.00 (3.29%)
Ex-Dividend Date	Nov 4, 2025

Volume	18,381
Average Volume	31,237
Open	913.25
Previous Close	913.12
Day's Range	892.00 - 919.90
52-Week Range	653.14 - 1,010.00
Beta	0.40
RSI	39.54
Earnings Date	Feb 6, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, rest of Asia, Africa, Australia, North America, the Middle East, and Europe. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products, as well as over-the-counter pharmaceutical products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to Vietnam, ...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 450
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2024, Haleon Pakistan's revenue was 37.21 billion, an increase of 17.70% compared to the previous year's 31.61 billion. Earnings were 4.58 billion, an increase of 359.85%.